Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohan Hazra

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Antiviral Therapy|February 19, 2014
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumaratePeter L Havens, Rohan Hazra, Charles B Stephensen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2015
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During PregnancyGeorge K Siberry, Denise L Jacobson, Heidi J Kalkwarf, et al.
Antimicrobial Agents and Chemotherapy|September 5, 2013
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?Peter L Havens, Jennifer J Kiser, Charles B Stephensen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled TrialPeter L Havens, Charles B Stephensen, Marta D Van Loan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL responseMargaret E Feeney, Yanhua Tang, Katja Pfafferott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2016
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure ProphylaxisPeter L Havens, Charles B Stephensen, Marta D Van Loan, et al.
AIDS (London, England)|March 23, 2021
In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newbornsShu-Hong Lin, Youjin Wang, Stephen W Hartley, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
The Journal of Infectious Diseases|May 19, 2021
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn InfantsElizabeth J McFarland, Coleen K Cunningham, Petronella Muresan, et al.
The Journal of Infectious Diseases|November 5, 2019
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn InfantsColeen K Cunningham, Elizabeth J McFarland, R Leavitt Morrison, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Antiviral Therapy|February 19, 2014
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumaratePeter L Havens, Rohan Hazra, Charles B Stephensen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2015
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During PregnancyGeorge K Siberry, Denise L Jacobson, Heidi J Kalkwarf, et al.
Antimicrobial Agents and Chemotherapy|September 5, 2013
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?Peter L Havens, Jennifer J Kiser, Charles B Stephensen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled TrialPeter L Havens, Charles B Stephensen, Marta D Van Loan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL responseMargaret E Feeney, Yanhua Tang, Katja Pfafferott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2016
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure ProphylaxisPeter L Havens, Charles B Stephensen, Marta D Van Loan, et al.
AIDS (London, England)|March 23, 2021
In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newbornsShu-Hong Lin, Youjin Wang, Stephen W Hartley, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
The Journal of Infectious Diseases|May 19, 2021
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn InfantsElizabeth J McFarland, Coleen K Cunningham, Petronella Muresan, et al.
The Journal of Infectious Diseases|November 5, 2019
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn InfantsColeen K Cunningham, Elizabeth J McFarland, R Leavitt Morrison, et al.
Pageof 15